 [1m([0morchestrator-aplastic anemia-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes EXTENDED PHENYTOIN SODIUM increase or decrease the[0m
[34mrisk of aplastic anemia?[0m
 [1m([0morchestrator-aplastic anemia-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-aplastic anemia-EXTENDED PHENYTOIN SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does EXTENDED PHENYTOIN SODIUM increase or decrease the risk of aplastic anemia?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-aplastic anemia-EXTENDED PHENYTOIN SODIUM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes EXTENDED PHENYTOIN SODIUM increase or decrease the[0m
[32mrisk of aplastic anemia?[0m
 [1m([0morchestrator-aplastic anemia-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-aplastic anemia-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes EXTENDED PHENYTOIN SODIUM increase or decrease the risk of aplastic anemia?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does extended phenytoin sodium increase the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"extended phenytoin sodium"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: EXTENDED PHENYTOIN SODIUM: adverse_reactions: [0m[1;31m6[0m[31m ADVERSE REACTIONS The following serious adverse reactions are described elsewhere in the labeling: Withdrawal Precipitated Seizure, Status [0m
[31mEpilepticus [0m[31m Suicidal Behavior and Ideation [0m[31m Serious Dermatologic Reactions [0m[31m Drug Reaction with Eosinophilia and Systemic Symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m/[0m[31mMultiorgan[0m[31m Hypersensitivity [0m[31m Hypersensitivity [0m[31m Cardiac [0m
[31mEffects [0m[31m Angioedema [0m[31m Hepatic Injury [0m[31m Hematopoietic Complications [0m[31m Effects on Vitamin D and Bone [0m[31m Exacerbation of Porphyria [0m[31m Teratogenicity and Other Harm to the Newborn [0m[31m Hyperglycemia [0m[1;31m[[0m[31m see Warnings [0m
[31mand Precautions [0m[1;31m([0m[1;31m5.14[0m[1;31m)[0m[31m [0m[1;31m][0m[31m The following adverse reactions associated with the use of phenytoin were identified in clinical studies or postmarketing reports. Because these reactions are reported [0m
[31mvoluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. EXTENDED PHENYTOIN SODIUM: [0m
[31madverse_reactions: Body as a Whole: Allergic reactions in the form of rash and rarely more serious forms and DRESS have been observed, as has angioedema [0m[31m . Anaphylaxis has also been reported. There [0m
[31mhave also been reports of coarsening of facial features, systemic lupus erythematosus, periarteritis nodosa, and immunoglobulin abnormalities. Digestive System: Acute hepatic failure, toxic hepatitis,[0m
[31mliver damage, nausea, vomiting, constipation, enlargement of the lips, and gingival hyperplasia. Hematologic and Lymphatic System: Hematopoietic complications, some fatal, have occasionally been [0m
[31mreported in association with administration of phenytoin. EXTENDED PHENYTOIN SODIUM: adverse_reactions: These have included thrombocytopenia, leukopenia, granulocytopenia, agranulocytosis, and [0m
[31mpancytopenia with or without bone marrow suppression. While macrocytosis and megaloblastic anemia have occurred, these conditions usually respond to folic acid therapy. Lymphadenopathy including [0m
[31mbenign lymph node hyperplasia, pseudolymphoma, lymphoma, and Hodgkinâ€™s disease have been reported [0m[31m . Pure red cell aplasia has also been reported. Laboratory Test Abnormality: Phenytoin may decrease [0m
[31mserum concentrations of thyroid hormone [0m[1;31m([0m[31mT4 and T3[0m[1;31m)[0m[31m, sometimes with an accompanying increase in thyroid-stimulating hormone [0m[1;31m([0m[31mTSH[0m[1;31m)[0m[31m, but usually in the absence of clinical hypothyroidism. Phenytoin may [0m
[31malso produce lower than normal values for dexamethasone or metyrapone tests. EXTENDED PHENYTOIN SODIUM: adverse_reactions: Phenytoin may cause increased serum levels of glucose [0m[1;31m[[0m[31m see Warnings and [0m
[31mPrecautions [0m[1;31m([0m[1;31m5.14[0m[1;31m)[0m[31m [0m[1;31m][0m[31m , alkaline phosphatase, and gamma glutamyl transpeptidase [0m[1;31m([0m[31mGGT[0m[1;31m)[0m[31m. Nervous System: The most common adverse reactions encountered with phenytoin therapy are nervous system reactions [0m
[31mand are usually dose-related. Reactions include nystagmus, ataxia, slurred speech, decreased coordination, somnolence, and mental confusion. Dizziness, vertigo, insomnia, transient nervousness, motor [0m
[31mtwitchings, paresthesias, and headaches have also been observed. There have also been rare reports of phenytoin-induced dyskinesias, including chorea, dystonia, tremor and asterixis, similar to those [0m
[31minduced by phenothiazine and other neuroleptic drugs. EXTENDED PHENYTOIN SODIUM: adverse_reactions: Cerebellar atrophy has been reported, and appears more likely in settings of elevated phenytoin [0m
[31mlevels and/or long-term phenytoin use [0m[1;31m[[0m[31m see Warnings and Precautions [0m[1;31m([0m[1;31m5.15[0m[1;31m)[0m[31m [0m[1;31m][0m[31m . A predominantly sensory peripheral polyneuropathy has been observed in patients receiving long-term phenytoin therapy. [0m
[31mSkin and Appendages: Dermatological manifestations sometimes accompanied by fever have included scarlatiniform or morbilliform rashes. A morbilliform rash [0m[1;31m([0m[31mmeasles-like[0m[1;31m)[0m[31m is the most common; other [0m
[31mtypes of dermatitis are seen more rarely. Other more serious forms which may be fatal have included bullous, exfoliative or purpuric dermatitis, acute generalized exanthematous pustulosis, [0m
[31mStevens-Johnson syndrome, and toxic epidermal necrolysis [0m[31m . There have also been reports of hypertrichosis and urticaria.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m


[31mCONTENT: EXTENDED PHENYTOIN SODIUM: spl_medguide: MEDICATION GUIDE Dispense with Medication Guide available at: documents.amneal.com/mg/extended-phenytoin-sodium.pdf Extended phenytoin sodium [0m[1;31m([0m[31mfenâ€˜ i [0m
[31mtoyn soeâ€˜ dee um[0m[1;31m)[0m[31m capsules What is the most important information I should know about extended phenytoin sodium capsules? [0m[1;31m1[0m[31m. Do not stop taking extended phenytoin sodium capsules without first talking[0m
[31mto your healthcare provider. Stopping extended phenytoin sodium capsules suddenly can cause serious problems. Stopping a seizure medicine suddenly can cause you to have seizures more often or seizures[0m
[31mthat will not stop [0m[1;31m([0m[31mstatus epilepticus[0m[1;31m)[0m[31m. [0m[1;31m2[0m[31m. Like other antiepileptic drugs, extended phenytoin sodium capsules may cause suicidal thoughts or actions in a very small number of people, about [0m[1;31m1[0m[31m in [0m[1;31m500[0m[31m. [0m
[31mEXTENDED PHENYTOIN SODIUM: spl_medguide: Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you: Thoughts about suicide or dying New [0m
[31mor worse anxiety Trouble sleeping [0m[1;31m([0m[31minsomnia[0m[1;31m)[0m[31m Acting on dangerous impulses Attempts to commit suicide Feeling agitated or restless New or worse irritability An extreme increase in activity and talking [0m
[1;31m([0m[31mmania[0m[1;31m)[0m[31m New or worse depression Panic attacks Acting aggressive, being angry, or violent Other unusual changes in behavior or mood Suicidal thoughts or actions can be caused by things other than [0m
[31mmedicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes. How can I watch for early symptoms of suicidal thoughts and actions? Pay attention to any [0m
[31mchanges, especially sudden changes, in mood, behaviors, thoughts, or feelings. Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as [0m
[31mneeded, especially if you are worried about symptoms. [0m[1;31m3[0m[31m. EXTENDED PHENYTOIN SODIUM: spl_medguide: Extended phenytoin sodium capsules can cause a type of serious allergic reaction that may affect [0m
[31mdifferent parts of the body such as your liver, kidneys, blood, heart, skin or other parts of your body. These can be very serious and cause death. Call your healthcare provider right away if you have[0m
[31many or all of these symptoms: Fever Sore throat Not wanting to eat [0m[1;31m([0m[31manorexia[0m[1;31m)[0m[31m Rash Sores in your mouth Nausea Swollen lymph glands Bruise easily Vomiting Swelling of your face, eye, lips, or tongue [0m
[31mTrouble swallowing or breathing Purple or red spots on your skin Increase infections Yellowing of the skin and the white part of your eyes [0m[1;31m([0m[31mjaundice[0m[1;31m)[0m[31m Call your healthcare provider even if the symptoms[0m
[31mare mild or if you have been taking extended phenytoin sodium capsules for an extended period of time. These symptoms can be a sign of a serious allergic reaction. [0m[1;31m4[0m[31m. EXTENDED PHENYTOIN SODIUM: [0m
[31mspl_medguide: Extended phenytoin sodium capsules can cause problems with your heart, including a slow heartbeat. Let your healthcare provider know right away if you have any of these symptoms: [0m
[31mdizziness tiredness feeling like your heart is beating slowly or skipping beats chest pain What are extended phenytoin sodium capsules? Extended phenytoin sodium capsules are a prescription medicine [0m
[31mused to treat certain types of seizures called tonic-clonic [0m[1;31m([0m[31mgrand mal[0m[1;31m)[0m[31m and psychomotor [0m[1;31m([0m[31mtemporal lobe[0m[1;31m)[0m[31m seizures. Do not take extended phenytoin sodium capsules if you: Are allergic to phenytoin or [0m
[31many of the ingredients in extended phenytoin sodium capsules. See the end of this leaflet for a complete list of ingredients in extended phenytoin sodium capsules. Have had an allergic reaction to [0m
[31mCEREBYX [0m[1;31m([0m[31mfosphenytoin[0m[1;31m)[0m[31m, PEGANONE [0m[1;31m([0m[31methotoin[0m[1;31m)[0m[31m, or MESANTOIN [0m[1;31m([0m[31mmephenytoin[0m[1;31m)[0m[31m. EXTENDED PHENYTOIN SODIUM: spl_medguide: Have had liver problems from taking phenytoin. Take delavirdine. Before taking [0m
[31mextended phenytoin sodium capsules, tell your healthcare provider about all of your medical conditions, including if you: Have or have had depression, mood problems, or suicidal thoughts or behavior [0m
[31mHave had an allergic reaction to a medicine similar to extended phenytoin sodium capsules called carboxamides, barbiturates, succinimides, and oxazolidinediones Have or had liver or kidney problems [0m
[31mHave or had an enzyme problem called porphyria Have or had high blood sugar [0m[1;31m([0m[31mhyperglycemia[0m[1;31m)[0m[31m Drink alcohol Are pregnant or plan to become pregnant. Extended phenytoin sodium capsules may harm your [0m
[31munborn baby. If you take extended phenytoin sodium capsules during pregnancy, your baby is at risk for serious birth defects. EXTENDED PHENYTOIN SODIUM: spl_medguide: If you become pregnant while [0m
[31mtaking extended phenytoin sodium capsules, the level of phenytoin in your blood may decrease, causing your seizures to become worse. Your healthcare provider may change your dose of extended phenytoin[0m
[31msodium capsules. If you take extended phenytoin sodium capsules during pregnancy, your baby is also at risk for bleeding problems right after birth. Your healthcare provider may give you and your baby[0m
[31mmedicine to prevent this. All women of child-bearing age should talk to their healthcare provider about using other possible treatments instead of extended phenytoin sodium capsules. If you are of [0m
[31mchildbearing age and are not planning on getting pregnant, you should use effective birth control [0m[1;31m([0m[31mcontraception[0m[1;31m)[0m[31m while taking extended phenytoin sodium capsules. Pregnancy Registry: If you become [0m
[31mpregnant while taking extended phenytoin sodium capsules, talk to your healthcare provider about registering with the North American Antiepileptic Drug Pregnancy Registry. EXTENDED PHENYTOIN SODIUM: [0m
[31mspl_medguide: You can enroll in this registry by calling [0m[1;31m1[0m[31m-[0m[1;31m888[0m[31m-[0m[1;31m233[0m[31m-[0m[1;31m2334[0m[31m. The purpose of this registry is to collect information about the safety of antiepileptic drugs during pregnancy. Are [0m
[31mbreastfeeding or plan to breastfeed. Phenytoin can pass into breast milk. You and your healthcare provider should decide if you will take extended phenytoin sodium capsules while you are [0m
[31mbreastfeeding. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. These medicines can change the [0m
[31mlevels of phenytoin in your blood. Taking extended phenytoin sodium capsules with certain other medicines can cause side effects or affect how well they work. Do not start or stop other medicines [0m
[31mwithout talking to your healthcare provider. Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine. How should I take [0m
[31mextended phenytoin sodium capsules? EXTENDED PHENYTOIN SODIUM: spl_medguide: Take extended phenytoin sodium capsules exactly as your healthcare provider tells you. Your healthcare provider will tell [0m
[31myou how much extended phenytoin sodium capsules to take and when to take it. Your healthcare provider may change your dose if needed. Do not change your dose of extended phenytoin sodium capsules [0m
[31mwithout talking to your healthcare provider. Do not stop taking extended phenytoin sodium capsules without first talking to your healthcare provider. Stopping extended phenytoin sodium capsules [0m
[31msuddenly can cause serious problems. What should I avoid while taking extended phenytoin sodium capsules? Do not drink alcohol while you take extended phenytoin sodium capsules without first talking [0m
[31mto your healthcare provider. Drinking alcohol while taking extended phenytoin sodium capsules may change your blood levels of phenytoin which can cause serious problems. Do not drive, operate heavy [0m
[31mmachinery, or do other dangerous activities until you know how extended phenytoin sodium capsules affects you.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m


[31mCONTENT: EXTENDED PHENYTOIN SODIUM: spl_medguide_table: content>[0m[1;31m<[0m[31m/[0m[31mparagraph[0m[31m><paragraph>Extended phenytoin sodium capsules are a prescription medicine used to treat certain types of seizures called [0m
[31mtonic-clonic [0m[1;31m([0m[31mgrand mal[0m[1;31m)[0m[31m and psychomotor [0m[1;31m([0m[31mtemporal lobe[0m[1;31m)[0m[31m seizures.<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m" Botrule Toprule Lrule Rrule"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Do not [0m
[31mtake<[0m[31m/[0m[31mcontent[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>extended phenytoin sodium capsules if you:<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Disc"[0m[31m><item>Are allergic to phenytoin or any of the [0m
[31mingredients in extended phenytoin sodium capsules. See the end of this leaflet for a complete list of ingredients in extended phenytoin sodium capsules.<[0m[31m/[0m[31mitem[0m[31m><item>Have had an allergic reaction to [0m
[31mCEREBYX [0m[1;31m([0m[31mfosphenytoin[0m[1;31m)[0m[31m, PEGANONE [0m[1;31m([0m[31methotoin[0m[1;31m)[0m[31m, or MESANTOIN [0m[1;31m([0m[31mmephenytoin[0m[1;31m)[0m[31m. EXTENDED PHENYTOIN SODIUM: spl_medguide_table: item><item>Have had liver problems from taking phenytoin.<[0m[31m/[0m[31mitem[0m[31m><item>Take [0m
[31mdelavirdine.<[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Before taking<[0m[31m/[0m[31mcontent[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>extended phenytoin sodium capsules, tell your healthcare provider about all of your [0m
[31mmedical conditions, including if you:<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Disc"[0m[31m><item>Have or have had depression, mood problems, or suicidal thoughts or [0m
[31mbehavior<[0m[31m/[0m[31mitem[0m[31m><item>Have had an allergic reaction to a medicine similar to extended phenytoin sodium capsules called carboxamides, barbiturates, succinimides, and oxazolidinediones<[0m[31m/[0m[31mitem[0m[31m><item>Have [0m
[31mor had liver or kidney problems<[0m[31m/[0m[31mitem[0m[31m><item>Have or had an enzyme problem called porphyria<[0m[31m/[0m[31mitem[0m[31m><item>Have or had high blood sugar [0m[1;31m([0m[31mhyperglycemia[0m[1;31m)[0m[31m<[0m[31m/[0m[31mitem[0m[31m><item>Drink alcohol<[0m[31m/[0m[31mitem[0m[31m><item EXTENDED [0m
[31mPHENYTOIN SODIUM: spl_medguide_table: >Are pregnant or plan to become pregnant. Extended phenytoin sodium capsules may harm your unborn baby.<[0m[31m/[0m[31mitem[0m[31m><item>If you take extended phenytoin sodium capsules[0m
[31mduring pregnancy, your baby is at risk for serious birth defects.<[0m[31m/[0m[31mitem[0m[31m><item>If you become pregnant while taking extended phenytoin sodium capsules, the level of phenytoin in your blood may decrease,[0m
[31mcausing your seizures to become worse. Your healthcare provider may change your dose of extended phenytoin sodium capsules.<[0m[31m/[0m[31mitem[0m[31m><item>If you take extended phenytoin sodium capsules during pregnancy,[0m
[31myour baby is also at risk for bleeding problems right after birth. Your healthcare provider may give you and your baby medicine to prevent this.<[0m[31m/[0m[31mitem[0m[31m><item>All women of child-bearing age should talk [0m
[31mto their healthcare provider about using other possible treatments instead of extended phenytoin sodium capsules. EXTENDED PHENYTOIN SODIUM: spl_medguide_table: item><item>If you are of childbearing [0m
[31mage and are not planning on getting pregnant, you should use effective birth control [0m[1;31m([0m[31mcontraception[0m[1;31m)[0m[31m while taking extended phenytoin sodium capsules.<[0m[31m/[0m[31mitem[0m[31m><item><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Pregnancy [0m
[31mRegistry:<[0m[31m/[0m[31mcontent[0m[31m>If you become pregnant while taking extended phenytoin sodium capsules, talk to your healthcare provider about registering with the North American Antiepileptic Drug Pregnancy [0m
[31mRegistry. You can enroll in this registry by calling [0m[1;31m1[0m[31m-[0m[1;31m888[0m[31m-[0m[1;31m233[0m[31m-[0m[1;31m2334[0m[31m. The purpose of this registry is to collect information about the safety of antiepileptic drugs during pregnancy. <[0m[31m/[0m[31mitem[0m[31m><item>Are [0m
[31mbreastfeeding or plan to breastfeed. Phenytoin can pass into breast milk. You and your healthcare provider should decide if you will take extended phenytoin sodium capsules while you are [0m
[31mbreastfeeding. EXTENDED PHENYTOIN SODIUM: spl_medguide_table: item><[0m[31m/[0m[31mlist[0m[31m><paragraph>Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter [0m
[31mmedicines, vitamins, and herbal supplements. These medicines can change the levels of phenytoin in your blood.<[0m[31m/[0m[31mparagraph[0m[31m><paragraph>Taking extended phenytoin sodium capsules with certain other [0m
[31mmedicines can cause side effects or affect how well they work. Do not start or stop other medicines without talking to your healthcare provider.<[0m[31m/[0m[31mparagraph[0m[31m><paragraph>Know the medicines you take. Keep[0m
[31ma list of them and show it to your healthcare provider and pharmacist when you get a new medicine.<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m" Botrule Toprule Lrule Rrule"[0m[31m><paragraph><content [0m
[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>How should I take<[0m[31m/[0m[31mcontent[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[1;31m>[0m[31mextended phenytoin sodium capsules?         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m


[31mCONTENT: EXTENDED PHENYTOIN SODIUM: warnings_and_cautions: Anyone considering prescribing phenytoin sodium or any other AED must balance the risk of suicidal thoughts or behavior with the risk of [0m
[31muntreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. [0m
[31mShould suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being [0m
[31mtreated. Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or [0m
[31mworsening of the signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be[0m
[31mreported immediately to healthcare providers. [0m[1;31m5[0m[31m. EXTENDED PHENYTOIN SODIUM: warnings_and_cautions: [0m[1;31m3[0m[31m Serious Dermatologic Reactions Phenytoin sodium can cause severe cutaneous adverse reactions [0m
[1;31m([0m[31mSCARs[0m[1;31m)[0m[31m, which may be fatal. Reported reactions in phenytoin-treated patients have included toxic epidermal necrolysis [0m[1;31m([0m[31mTEN[0m[1;31m)[0m[31m, Stevens-Johnson syndrome [0m[1;31m([0m[31mSJS[0m[1;31m)[0m[31m, acute generalized exanthematous pustulosis[0m
[1;31m([0m[31mAGEP[0m[1;31m)[0m[31m, and Drug Reaction with Eosinophilia and Systemic Symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m [0m[31m . The onset of symptoms is usually within [0m[1;31m28[0m[31m days, but can occur later. Phenytoin sodium should be discontinued at the first [0m
[31msign of a rash, unless the rash is clearly not drug-related. If signs or symptoms suggest a severe cutaneous adverse reaction, use of this drug should not be resumed and alternative therapy should be [0m
[31mconsidered. If a rash occurs, the patient should be evaluated for signs and symptoms of SCARs. EXTENDED PHENYTOIN SODIUM: warnings_and_cautions: Studies in patients of Chinese ancestry have found a [0m
[31mstrong association between the risk of developing SJS/TEN and the presence of HLA-B*[0m[1;31m1502[0m[31m, an inherited allelic variant of the HLA-B gene, in patients using carbamazepine. Limited evidence suggests [0m
[31mthat HLA-B*[0m[1;31m1502[0m[31m may be a risk factor for the development of SJS/TEN in patients of Asian ancestry taking other antiepileptic drugs associated with SJS/TEN, including phenytoin. In addition, [0m
[31mretrospective, case-control, genome-wide association studies in patients of southeast Asian ancestry have also identified an increased risk of SCARs in carriers of the decreased function CYP2C9*[0m[1;31m3[0m[31m [0m
[31mvariant, which has also been associated with decreased clearance of phenytoin. EXTENDED PHENYTOIN SODIUM: warnings_and_cautions: Consider avoiding phenytoin as an alternative to carbamazepine in [0m
[31mpatients who are positive for HLA-B*[0m[1;31m1502[0m[31m or in CYP2C9*[0m[1;31m3[0m[31m carriers [0m[31m . The use of HLA-B*[0m[1;31m1502[0m[31m or CYP2C9 genotyping has important limitations and must never substitute for appropriate clinical vigilance [0m
[31mand patient management. The role of other possible factors in the development of, and morbidity from, SJS/TEN, such as antiepileptic drug [0m[1;31m([0m[31mAED[0m[1;31m)[0m[31m dose, compliance, concomitant medications, [0m
[31mcomorbidities, and the level of dermatologic monitoring have not been studied. [0m[1;31m5[0m[31m. EXTENDED PHENYTOIN SODIUM: warnings_and_cautions: [0m[1;31m4[0m[31m Drug Reaction with Eosinophilia and Systemic Symptoms [0m
[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m/[0m[31mMultiorgan[0m[31m Hypersensitivity Drug Reaction with Eosinophilia and Systemic Symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m, also known as Multiorgan hypersensitivity, has been reported in patients taking antiepileptic drugs, [0m
[31mincluding phenytoin sodium. Some of these events have been fatal or life-threatening. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling, in [0m
[31massociation with other organ system involvement, such as hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis sometimes resembling an acute viral infection. Eosinophilia is [0m
[31moften present. Because this disorder is variable in its expression, other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity, such as [0m
[31mfever or lymphadenopathy, may be present even though rash is not evident.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m


[31mCONTENT: EXTENDED PHENYTOIN SODIUM: warnings_and_cautions: [0m[1;31m6[0m[31m Cardiac Effects Cases of bradycardia and cardiac arrest have been reported in phenytoin sodium-treated patients, both at recommended [0m
[31mphenytoin doses and levels, and in association with phenytoin toxicity [0m[31m . Most of the reports of cardiac arrest occurred in patients with underlying cardiac disease. [0m[1;31m5.7[0m[31m Angioedema Angioedema has been[0m
[31mreported in patients treated with phenytoin sodium in the postmarketing setting. Phenytoin sodium should be discontinued immediately if symptoms of angioedema, such as facial, perioral, or upper [0m
[31mairway swelling occur. Phenytoin sodium should be discontinued permanently if a clear alternative etiology for the reaction cannot be established. [0m[1;31m5.8[0m[31m Hepatic Injury Cases of acute hepatotoxicity, [0m
[31mincluding infrequent cases of acute hepatic failure, have been reported with phenytoin sodium. EXTENDED PHENYTOIN SODIUM: warnings_and_cautions: These events may be part of the spectrum of DRESS or [0m
[31mmay occur in isolation [0m[31m. Other common manifestations include jaundice, hepatomegaly, elevated serum transaminase levels, leukocytosis, and eosinophilia. The clinical course of acute phenytoin [0m
[31mhepatotoxicity ranges from prompt recovery to fatal outcomes. In these patients with acute hepatotoxicity, phenytoin sodium should be immediately discontinued and not readministered. [0m[1;31m5.9[0m[31m Hematopoietic[0m
[31mComplications Hematopoietic complications, some fatal, have occasionally been reported in association with administration of phenytoin sodium. These have included thrombocytopenia, leukopenia, [0m
[31mgranulocytopenia, agranulocytosis, and pancytopenia with or without bone marrow suppression. EXTENDED PHENYTOIN SODIUM: warnings_and_cautions: There have been a number of reports suggesting a [0m
[31mrelationship between phenytoin and the development of lymphadenopathy [0m[1;31m([0m[31mlocal or generalized[0m[1;31m)[0m[31m including benign lymph node hyperplasia, pseudolymphoma, lymphoma, and Hodgkinâ€™s disease. Although a cause [0m
[31mand effect relationship has not been established, the occurrence of lymphadenopathy indicates the need to differentiate such a condition from other types of lymph node pathology. Lymph node [0m
[31minvolvement may occur with or without symptoms and signs of DRESS [0m[31m . In all cases of lymphadenopathy, follow-up observation for an extended period is indicated and every effort should be made to [0m
[31machieve seizure control using alternative antiepileptic drugs. [0m[1;31m5.10[0m[31m Effects on Vitamin D and Bone The chronic use of phenytoin in patients with epilepsy has been associated with decreased bone mineral[0m
[31mdensity [0m[1;31m([0m[31mosteopenia, osteoporosis, and osteomalacia[0m[1;31m)[0m[31m and bone fractures. EXTENDED PHENYTOIN SODIUM: warnings_and_cautions: Phenytoin induces hepatic metabolizing enzymes. This may enhance the [0m
[31mmetabolism of vitamin D and decrease vitamin D levels, which may lead to vitamin D deficiency, hypocalcemia, and hypophosphatemia. Consideration should be given to screening with bone-related [0m
[31mlaboratory and radiological tests as appropriate and initiating treatment plans according to established guidelines. [0m[1;31m5.11[0m[31m Renal or Hepatic Impairment or Hypoalbuminemia Because the fraction of unbound[0m
[31mphenytoin is increased in patients with renal or hepatic disease, or in those with hypoalbuminemia, the monitoring of phenytoin serum levels should be based on the unbound fraction in those patients. [0m
[1;31m5.12[0m[31m Exacerbation of Porphyria In view of isolated reports associating phenytoin with exacerbation of porphyria, caution should be exercised in using this medication in patients suffering from this [0m
[31mdisease. [0m[1;31m5[0m[31m. EXTENDED PHENYTOIN SODIUM: warnings_and_cautions: [0m[1;31m13[0m[31m Teratogenicity and Other Harm to the Newborn Phenytoin may cause fetal harm when administered to a pregnant woman. Prenatal exposure to[0m
[31mphenytoin may increase the risks for congenital malformations and other adverse developmental outcomes [0m[31m. Increased frequencies of major malformations [0m[1;31m([0m[31msuch as orofacial clefts and cardiac defects[0m[1;31m)[0m[31m, [0m
[31mand abnormalities characteristic of fetal hydantoin syndrome, including dysmorphic skull and facial features, nail and digit hypoplasia, growth abnormalities [0m[1;31m([0m[31mincluding microcephaly[0m[1;31m)[0m[31m, and cognitive [0m
[31mdeficits, have been reported among children born to epileptic women who took phenytoin alone or in combination with other antiepileptic drugs during pregnancy. There have been several reported cases [0m
[31mof malignancies, including neuroblastoma.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Extended phenytoin sodium has been associated with hematopoietic complications, some of which have been fatal. These complications include thrombocytopenia, leukopenia, granulocytopenia, [0m
[32magranulocytosis, and pancytopenia with or without bone marrow suppression. Pure red cell aplasia has also been reported. However, the frequency of these events is not reliably estimated, and a causal [0m
[32mrelationship to drug exposure is not always clear.[0m

[32mSOURCE: EXTENDED PHENYTOIN SODIUM label[0m
[32mEXTRACT_START_END: Hematopoietic complications, some fatal[0m[32m...[0m[32m Pure red cell aplasia has also been reported.[0m
*[1m([0morchestrator-aplastic anemia-EXTENDED PHENYTOIN SODIUM[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Extended phenytoin sodium has been associated [0m
[34mwith hematopoietic complications, some of which have been fatal. These complications include thrombocytopenia, leukopenia, granulocytopenia, agranulocytosis, and pancytopenia with or without bone [0m
[34mmarrow suppression. Pure red cell aplasia has also been reported. However, the frequency of these events is not reliably estimated, and a causal relationship to drug exposure is not always clear.[0m

[34mSOURCE: EXTENDED PHENYTOIN SODIUM label[0m
[34mEXTRACT_START_END: Hematopoietic complications, some fatal[0m[34m...[0m[34m Pure red cell aplasia has also been reported.[0m
 [1m([0morchestrator-aplastic anemia-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-aplastic anemia-EXTENDED PHENYTOIN SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does EXTENDED PHENYTOIN SODIUM increase or decrease the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether EXTENDED PHENYTOIN SODIUM increases or decreases the risk of aplastic anemia."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded by indicating that EXTENDED PHENYTOIN SODIUM has been associated with hematopoietic complications, some of which have been fatal, including thrombocytopenia, leukopenia, [0m
[32mgranulocytopenia, agranulocytosis, and pancytopenia with or without bone marrow suppression. Pure red cell aplasia has also been reported. However, the frequency of these events is not reliably [0m
[32mestimated, and a causal relationship to drug exposure is not always clear."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"EXTENDED PHENYTOIN SODIUM has been associated with hematopoietic complications, including conditions that affect the bone marrow and blood cells. These complications can be severe and [0m
[32msometimes fatal. While pure red cell aplasia has been reported, which is a condition related to aplastic anemia, the frequency of these events and the clarity of the causal relationship to the drug [0m
[32mare not well established. Therefore, it is known that there is an association, but the degree of risk and the reliability of the causal relationship are not clearly defined."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-aplastic anemia-EXTENDED PHENYTOIN SODIUM[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-aplastic anemia-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-aplastic anemia-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-aplastic anemia-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does EXTENDED PHENYTOIN SODIUM increase or decrease the risk of aplastic anemia?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether EXTENDED PHENYTOIN SODIUM increases or decreases the risk of aplastic anemia."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded by indicating that EXTENDED PHENYTOIN SODIUM has been associated with hematopoietic complications, some of which have been fatal, including thrombocytopenia, leukopenia, [0m
[34mgranulocytopenia, agranulocytosis, and pancytopenia with or without bone marrow suppression. Pure red cell aplasia has also been reported. However, the frequency of these events is not reliably [0m
[34mestimated, and a causal relationship to drug exposure is not always clear."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"EXTENDED PHENYTOIN SODIUM has been associated with hematopoietic complications, including conditions that affect the bone marrow and blood cells. These complications can be severe and [0m
[34msometimes fatal. While pure red cell aplasia has been reported, which is a condition related to aplastic anemia, the frequency of these events and the clarity of the causal relationship to the drug [0m
[34mare not well established. Therefore, it is known that there is an association, but the degree of risk and the reliability of the causal relationship are not clearly defined."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does EXTENDED PHENYTOIN SODIUM increase or decrease the risk of aplastic anemia?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether EXTENDED PHENYTOIN SODIUM increases or decreases the risk of aplastic anemia.[0m
[1;31m2[0m[31m. FDAHandler responded by indicating that EXTENDED PHENYTOIN SODIUM has been associated with hematopoietic complications, some of which have been fatal, including thrombocytopenia, leukopenia, [0m
[31mgranulocytopenia, agranulocytosis, and pancytopenia with or without bone marrow suppression. Pure red cell aplasia has also been reported. However, the frequency of these events is not reliably [0m
[31mestimated, and a causal relationship to drug exposure is not always clear.[0m
[31m        -----[0m
[31m        Final answer: EXTENDED PHENYTOIN SODIUM has been associated with hematopoietic complications, including conditions that affect the bone marrow and blood cells. These complications can be [0m
[31msevere and sometimes fatal. While pure red cell aplasia has been reported, which is a condition related to aplastic anemia, the frequency of these events and the clarity of the causal relationship to [0m
[31mthe drug are not well established. Therefore, it is known that there is an association, but the degree of risk and the reliability of the causal relationship are not clearly defined.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The reasoning provided is consistent with the information given by FDAHandler and aligns with medical knowledge regarding drug side effects and their reporting. The response [0m
[32macknowledges the association between EXTENDED PHENYTOIN SODIUM and hematopoietic complications, including conditions related to aplastic anemia, while also correctly stating that the frequency and [0m
[32mcausal relationship are not well established. There are no apparent logical flaws in the reasoning process, and the final answer appropriately reflects the strength of evidence and the magnitude of [0m
[32mthe effect as being uncertain."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-aplastic anemia-EXTENDED PHENYTOIN SODIUM[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The reasoning provided is consistent with the information given by FDAHandler and aligns with medical knowledge regarding drug side effects and their reporting. The response [0m
[34macknowledges the association between EXTENDED PHENYTOIN SODIUM and hematopoietic complications, including conditions related to aplastic anemia, while also correctly stating that the frequency and [0m
[34mcausal relationship are not well established. There are no apparent logical flaws in the reasoning process, and the final answer appropriately reflects the strength of evidence and the magnitude of [0m
[34mthe effect as being uncertain."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-aplastic anemia-EXTENDED PHENYTOIN SODIUM[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The reasoning provided is consistent with the information given by FDAHandler and aligns with medical knowledge regarding drug side effects and their reporting. The response [0m
[31macknowledges the association between EXTENDED PHENYTOIN SODIUM and hematopoietic complications, including conditions related to aplastic anemia, while also correctly stating that the frequency and [0m
[31mcausal relationship are not well established. There are no apparent logical flaws in the reasoning process, and the final answer appropriately reflects the strength of evidence and the magnitude of [0m
[31mthe effect as being uncertain.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0morchestrator-aplastic anemia-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-aplastic anemia-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-aplastic anemia-EXTENDED PHENYTOIN SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe question was whether EXTENDED PHENYTOIN SODIUM increases or decreases the risk of aplastic anemia. According to the information provided by FDAHandler, EXTENDED PHENYTOIN SODIUM has been [0m
[32massociated with various hematopoietic complications, some of which have been fatal. These complications include a range of conditions that affect the bone marrow and blood cells, such as [0m
[32mthrombocytopenia, leukopenia, granulocytopenia, agranulocytosis, and pancytopenia, with or without bone marrow suppression. Additionally, pure red cell aplasia, which is related to aplastic anemia, [0m
[32mhas been reported. However, the frequency of these events and the clarity of the causal relationship to the drug are not well established.[0m

[32mTherefore, while there is an association between EXTENDED PHENYTOIN SODIUM and hematopoietic complications, including conditions related to aplastic anemia, the degree of risk and the reliability of [0m
[32mthe causal relationship are not clearly defined.[0m
